Skip to evidence report

GRNLSA.p53_damage: Studies — page 13

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 297 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for GRNLSA.p53_damage
#Trait / studyIndividual trait IDMean IC score
12001PPP1R14D levelsGCST904703035.21e-06
12002Omega-3 fatty acids to total fatty acids percentageGCST905024605.18e-06
12003ATOX1/TMSB10 ratioGCST903133775.18e-06
12004Spirits likingGCST900948485.18e-06
12005TNFSF12 levelsGCST902748465.17e-06
12006IDP dMRI ProbtrackX L1 slf rGCST900042685.12e-06
12007Prescriptions - ACE inhibitor|anti-hypertensiveUKBB000006575.09e-06
12008OSM levelsGCST904701335.09e-06
12009Type 1 diabetesGCST900140235.04e-06
12010Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T47ECGU0000474.94e-06
12011Crohns diseaseGCST904681214.94e-06
12012CEACAM21 levelsGCST904686944.80e-06
12013Neutrophill percentage | Blood countUKBB000004984.79e-06
12014LRCH4 levelsGCST904697914.69e-06
12015Breast cancerGCST900185794.50e-06
12016VWC2L levelsGCST904710634.48e-06
12017Physical activity (Total log acceleration)GCST900614084.47e-06
12018ADD1 levelsGCST904682334.44e-06
12019Types of physical activity in last 4 weeks - Heavy DIY (eg: weeding, lawn mowing, carpentry, digging) | Physical activityUKBB000008704.42e-06
12020Sphingomyelin_33:1_[M+H]1+ levelsGCST900602294.39e-06
12021Chronic heart failureGCST900185864.38e-06
12022CD4/LILRB4 ratioGCST903138434.31e-06
12023Actinic keratosisFING000000134.25e-06
12024ADAMTS15 levelsGCST904682234.24e-06
12025Iron deficiency anaemiaFING000006994.22e-06
12026Coffee intake (standard GWA)GCST902672744.19e-06
12027FAM3B/FUT3_FUT5 ratioGCST903147774.17e-06
12028aparc-Desikan lh area precuneusGCST900030974.14e-06
12029T1 FreeSurfer aseg Right-choroid-plexusGCST903841704.12e-06
12030Lymphocyte count | Blood countUKBB000004114.09e-06
12031Accelerometer-based physical activity measurement (average acceleration)GCST0060994.08e-06
12032KDM3A levelsGCST904696714.02e-06
12033HPCAL1/MPIG6B ratioGCST903150734.01e-06
12034aparc-a2009s lh thickness G-cuneusGCST900036133.97e-06
12035TNFRSF11A levelsGCST902776443.88e-06
12036Plasma sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* levels in chronic kidney diseaseGCST902659713.84e-06
12037Clonal hematopoiesis (DNMT3A mutation)GCST904353543.81e-06
12038PPM1F levelsGCST904702973.79e-06
12039Paroxysmal tachycardiaFING000011513.73e-06
12040Herring likingGCST900947813.70e-06
12041MAVS/RNF41 ratioGCST903153953.67e-06
12042ABHD14B/SPARC ratioGCST903131463.64e-06
12043Nonsuppurative otitis mediaFING000008853.61e-06
12044Neutrophill percentage (UKB data field 30200)GCST904680933.61e-06
12045Stroke (MTAG)GCST904490633.56e-06
12046CD79B/ICAM3 ratioGCST903139013.48e-06
12047Alcoholic liver diseaseFING000000573.47e-06
12048SCGB3A2 levelsGCST904705433.47e-06
12049Interpolated Year when non-cancer illness first diagnosed | Medical conditionsUKBB000003713.44e-06
12050TRIM5 levelsGCST904709703.43e-06
12051Hashimoto thyroiditisGCST900186353.43e-06
12052Breast cancerGCST0072363.39e-06
12053CD27/TNFRSF13B ratioGCST903137773.38e-06
12054MS-disease / Multiple SclerosisFING000008393.36e-06
12055Ulcerative colitisGCST904467953.35e-06
12056Physical activityGCST900933223.33e-06
12057DTI TBSS MD Posterior limb of internal capsule LGCST903845913.32e-06
12058Mean arterial pressure, manual reading, adjusted by medication | Cardiovascular measurementUKBB000004433.32e-06
12059aparc-a2009s lh area G-oc-temp-med-LingualGCST900033183.31e-06
12060DDC levelsGCST904689673.29e-06
12061Hypertensive Heart DiseaseFING000006393.29e-06
12062Type 1 diabetes with ketoacidosis (PheCode 250.11)GCST904756623.26e-06
12063Seborrheic keratosis (PheCode 702.2)GCST904762063.23e-06
12064Body fat rateGCST902786193.21e-06
12065QC T2 FLAIR-to-T1 linear alignment discrepancyGCST900063503.20e-06
12066GSTA1/KRT18 ratioGCST903149933.20e-06
12067Varicose veinsGCST900861443.14e-06
12068Active to sedentary transition probabilityGCST900614293.12e-06
12069FABP1/FABP2 ratioGCST903147503.09e-06
12070CD27/FCRL5 ratioGCST903137723.06e-06
12071FIS1/PDGFB ratioGCST903148303.03e-06
12072lymphocyte (fraction, mean, inv-norm transformed)GCST904754353.00e-06
12073XPNPEP2 levelsGCST904710842.94e-06
12074aseg global volume WM-hypointensitiesGCST900026042.94e-06
12075KLRD1/LY9 ratioGCST903152612.88e-06
12076Blood cell traits latent factor 22 (white cell)GCST905592642.88e-06
12077DNA methylation PhenoAge accelerationGCST900142922.80e-06
12078Blood cell traits latent factor 9 (white cell)GCST905592512.76e-06
12079Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T304ECGA0003042.75e-06
12080Degeneration of macula and posterior pole of retina (PheCode 362.2)GCST904758492.74e-06
12081lymphocyte (fraction, maximum, inv-norm transformed)GCST904754322.72e-06
12082MGAT2 levelsGCST900895602.70e-06
12083Type1 diabetes, definitions combined, early onsetFING000013842.67e-06
12084White bread likingGCST900948652.67e-06
12085PDE5A levelsGCST904701872.62e-06
12086Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35)GCST903093692.61e-06
12087Thyroid peroxidase antibody positivity with euthyroid in pregnancyGCST904352032.59e-06
12088LRP11/ROR1 ratioGCST903153302.57e-06
12089F2R/TNFRSF14 ratioGCST903147392.55e-06
12090CCL19 levelsGCST904685712.45e-06
12091F-wine liking (derived food-liking factor)GCST900948722.35e-06
12092IL19 levelsGCST904695682.34e-06
12093LRRC37A2 levelsGCST904698022.34e-06
12094PLAUR levelsGCST900120512.33e-06
12095Crohn's disease of large intestineFING000003682.29e-06
12096Neutrophil percentage of white cellsGCST0046332.29e-06
12097RSPO1/RSPO3 ratioGCST903157902.27e-06
12098Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T297ECGA0002972.25e-06
12099aparc-a2009s lh area G-postcentralGCST900033242.22e-06
12100Falls/tendency to fallFING000005302.20e-06
12101Felt very upset when reminded of stressful experience in past month | Traumatic eventsUKBB000002432.20e-06
12102RGMB levelsGCST902426472.13e-06
12103HypothyroidismGCST904681382.12e-06
12104Degree of unsaturationGCST905027462.12e-06
12105CDH3/NECTIN4 ratioGCST903139522.11e-06
12106Free thyroxine levels within normal range in pregnancyGCST904351962.09e-06
12107INHBB levelsGCST904696142.05e-06
12108Left-hemisphere limbic network to right-hemisphere default mode network white-matter structural connectivityGCST903027352.03e-06
12109Thyroid peroxidase antibody positivity in pregnancyGCST904352022.03e-06
12110Obesity due to excess caloriesFING000008962.01e-06
12111GIMAP7 levelsGCST904693452.01e-06
12112Treatment/medication code - ramipril | MedicationsUKBB000008562.00e-06
12113Lymphocyte percentage | Blood countUKBB000004122.00e-06
12114FGFBP3 levelsGCST904692321.99e-06
12115Rash and other nonspecific skin eruption (PheCode 687.1)GCST904761671.96e-06
12116Lymphocyte percentage (UKB data field 30180)GCST904680831.94e-06
12117Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T296ECGA0002961.91e-06
12118Raynauds phenomenon diseaseGCST902717131.90e-06
12119Lymphocyte percentage of white cellsGCST900023891.80e-06
12120Ulcerative colitis, NASFING000013901.77e-06
12121F-sweet food liking (derived food-liking factor)GCST900948541.75e-06
12122Invitation to complete online 24-hour recall dietary questionnaire, acceptance | Online follow-up - Diet by 24-hour recallUKBB000003781.73e-06
12123Number of treatments/medications taken | MedicationsUKBB000005421.71e-06
12124Systolic blood pressure, manual reading, adjusted by medication | Cardiovascular measurementUKBB000008111.70e-06
12125DTI TBSS L1 Genu of corpus callosumGCST903844301.69e-06
12126Cough on most days | Medical informationUKBB000001531.69e-06
12127End-diastolic bi-ventricular shape (principal component 10)GCST904484891.67e-06
12128Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T45ECGU0000451.65e-06
12129Systolic blood pressureGCST903016961.65e-06
12130GABBR2 levelsGCST902412301.64e-06
12131CCL5/SELP ratioGCST903137051.60e-06
12132DTI autoptx FA ifo l tractGCST903851241.58e-06
12133Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditionsUKBB000003691.58e-06
12134Ximenoylcarnitine (C26:1) levelsGCST902001491.57e-06
12135T1 CAT volume R RightThalamusGCST903840971.57e-06
12136Plasma lysine levels in chronic kidney diseaseGCST902654591.54e-06
12137Carcinoma in situ of breast, intraductal (controls excluding all cancers)FING000002401.53e-06
12138Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levelsGCST902001051.52e-06
12139F2R/PDGFB ratioGCST903147331.50e-06
12140ICD10 O60: Preterm labor and deliveryGCST904542421.49e-06
12141NFATC1/SPRY2 ratioGCST903155391.48e-06
12142Ceramide (d18:1/24:0) levelsGCST900240461.47e-06
12143AppendectomyFING000001041.46e-06
12144aseg lh intensity PutamenGCST900037701.46e-06
12145rfMRI amplitudes (ICA100 node 7)GCST900045951.45e-06
12146ZP3 levelsGCST904711051.45e-06
12147CEACAM16 levelsGCST904686891.43e-06
12148Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T44ECGU0000441.41e-06
12149Cardiac conduction disorders (PheCode 426)GCST904759521.39e-06
12150aseg rh volume Accumbens-areaGCST900026431.32e-06
12151Gestational diabetes mellitusGCST905664191.30e-06
12152Family relationship satisfaction | Mental healthUKBB000002381.29e-06
12153PF4 levelsGCST904702111.28e-06
12154Mean arterial pressure, manual reading, adjusted by medication | Cardiovascular measurementUKBB000004441.28e-06
12155Mucosal proctocolitisFING000008411.24e-06
12156T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 54)GCST903208731.20e-06
12157Systolic blood pressure, manual reading, adjusted by medication | Cardiovascular measurementUKBB000008121.19e-06
12158DBNL/PDGFB ratioGCST903144221.09e-06
12159IDP dMRI TBSS FA Sagittal stratum RGCST900039071.08e-06
12160Oxalate (ethanedioate) levelsGCST901996721.07e-06
12161PCOLCE levelsGCST904701751.06e-06
12162Mental and behavioural disorders due to use of tobacco | Mental and behavioural disorders due to psychoactive substance useUKBB000004601.05e-06
12163LY6D/NECTIN4 ratioGCST903153441.05e-06
12164IDP T1 FAST ROIs V cerebellum VIIbGCST900025761.05e-06
12165CXCL10 levelsGCST904689231.02e-06
12166FGF2/HBEGF ratioGCST903148111.02e-06
12167Recurrent or chronic depressionFING000012439.64e-07
12168HayfeverGCST904681319.62e-07
12169aparc-a2009s rh volume G-postcentralGCST900030269.44e-07
12170Estrone 3-sulfate metabolite levelGCST906163839.41e-07
12171Tobacco use disorder | mental disordersUKBB000008249.19e-07
12172Repeated disturbing thoughts of stressful experience in past month | Traumatic eventsUKBB000007509.17e-07
12173KRT18 levelsGCST904697169.14e-07
12174Chromatiales abundance in stoolGCST900323189.06e-07
12175IDP T1 SIENAX peripheral grey unnormalised volumeGCST900024278.95e-07
12176DLL1/NOTCH1 ratioGCST903144988.80e-07
12177HypertensionGCST900860918.76e-07
12178Acquired hypothyroidism (PheCode 244.2)GCST904756508.61e-07
12179Light-intensity physical activity durationGCST900614218.61e-07
12180Preterm labour and deliveryFING000012098.32e-07
12181DAB2/NCK2 ratioGCST903143678.22e-07
12182CD27/ICAM3 ratioGCST903137737.87e-07
12183Glycosyl ceramide (d18:1/20:0, d16:1/22:0) levelsGCST902001457.64e-07
12184CDH2/SSC4D ratioGCST903139517.37e-07
12185CD48/FCRL6 ratioGCST903138407.35e-07
12186IDP dMRI TBSS ICVF Tapetum RGCST900043737.35e-07
12187Colon cancer (PheCode 153.2)GCST904755677.34e-07
12188PPBP levelsGCST904702897.29e-07
12189Diabetes (confirmatory factor analysis Factor 28)GCST903093627.12e-07
12190IDP dMRI ProbtrackX OD ilf rGCST900044657.08e-07
12191Colorectal cancer (PheCode 153)GCST904755666.88e-07
12192All pneumoniaeFING000000656.88e-07
12193CHMP1A/RHOC ratioGCST903140536.84e-07
12194IDP T1 FAST ROIs R cerebellum VIIIaGCST900025806.66e-07
12195ITGB1BP2/SKAP2 ratioGCST903152196.48e-07
12196CD48 levelsGCST904686356.38e-07
12197ICAM3/NOTCH1 ratioGCST903151226.37e-07
12198NCR1 levelsGCST904700096.30e-07
12199TPSAB1 levelsGCST904709516.23e-07
12200Systolic blood pressure, manual reading | Blood pressureUKBB000008106.22e-07
12201Secondary diabetes mellitus (PheCode 249)GCST904756556.22e-07
12202FAS levelsGCST904277026.18e-07
12203REST UKBBICA NODEamps25 0006GCST903854896.10e-07
12204MelanomaGCST900118096.09e-07
12205Treatment/medication code - omeprazole | MedicationsUKBB000008525.76e-07
12206Frontotemporal dementiaFING000005605.68e-07
12207Nontoxic nodular goiter | endocrine/metabolicUKBB000005295.43e-07
12208ATP5IF1/METAP1D ratioGCST903133915.31e-07
12209CXCL11/DKK1 ratioGCST903143345.28e-07
12210Non-cancer illness code, self-reported - migraine | Medical conditionsUKBB000005205.26e-07
12211Type 1 diabetes, definitions combinedFING000013805.24e-07
12212AGR3 levelsGCST904682545.16e-07
12213CSF2 levelsGCST904688845.06e-07
12214Left-hemisphere salience/ventral attention network to hippocampus white-matter structural connectivityGCST903027234.99e-07
12215DOK2/PPP1R12A ratioGCST903145364.96e-07
12216Ceramide (d16:1/24:0) levelsGCST900252664.88e-07
12217Acute bronchitisFING000000214.80e-07
12218BA-exvivo rh area BA2GCST900032224.79e-07
12219BA-exvivo lh area BA1GCST900032074.77e-07
12220RAB31 levelsGCST900875524.74e-07
12221Ulcerative colitisGCST0041334.73e-07
12222EDAR/IPCEF1 ratioGCST903145784.52e-07
12223Milk type used - Skimmed | DietUKBB000004704.45e-07
12224AK1 levelsGCST904682694.20e-07
12225FOLR3/KLK8 ratioGCST903148684.12e-07
12226Major dietary changes in the last 5 years - Yes, because of other reasons | DietUKBB000004234.02e-07
12227Thyroid peroxidase antibody levels in pregnancyGCST904352013.96e-07
12228PDGFB/USP8 ratioGCST903156333.92e-07
12229Regional enteritis (PheCode 555.1)GCST904760663.55e-07
12230Barrett's esophagusGCST0037383.52e-07
12231CASP3/SERPINE1 ratioGCST903136433.52e-07
12232LPO levelsGCST904697893.50e-07
12233aparc-DKTatlas rh area precuneusGCST900032883.35e-07
12234Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST900425353.34e-07
12235CSF3 levelsGCST904688863.30e-07
12236Plasma X-26054 levels in chronic kidney diseaseGCST902668583.23e-07
12237MAVS/MED18 ratioGCST903153893.20e-07
12238MAPRE3 levelsGCST904698593.19e-07
12239DSC2/SPINT1 ratioGCST903145573.17e-07
12240IDP dMRI TBSS L2 Cingulum cingulate gyrus RGCST900041573.06e-07
12241TNFRSF10B levelsGCST900120212.97e-07
12242GDF15 levelsGCST904693212.80e-07
12243IDP T1 SIENAX peripheral grey normalised volumeGCST900024262.77e-07
12244Taking other prescription medications | MedicationUKBB000008132.75e-07
12245DTI TBSS L3 Genu of corpus callosumGCST903845262.55e-07
12246FCRL5/ICAM3 ratioGCST903148022.48e-07
12247COPD/asthma/ILD related infectionsFING000003532.29e-07
12248aparc-Desikan rh area precuneusGCST900031312.21e-07
12249Hard cheese likingGCST900947782.18e-07
12250NPTX1 levelsGCST904700782.10e-07
12251Degree of unsaturationGCST905027342.10e-07
12252HEXIM1/NT5C3A ratioGCST903150482.09e-07
12253Varicose veins of lower extremity (PheCode 454.1)GCST904760132.01e-07
12254Acetone levelsGCST900928051.73e-07
12255Selective deficiency of immunoglobulin G [IgG] subclassesFING000012881.71e-07
12256PsoriasisGCST904681471.61e-07
12257Breakthrough COVID-19 susceptibility after at least one dose of a COVID-19 vaccineGCST904486951.56e-07
12258FCRL6/GZMA ratioGCST903148061.54e-07
12259EDIL3 levelsGCST904690721.40e-07
12260IDP dMRI ProbtrackX L1 ifo lGCST900042581.31e-07
12261ENO2/PLXNA4 ratioGCST903146651.27e-07
12262Milk type used: Full cream (UKB data field 1418_1)GCST901329381.21e-07
12263KLRF1 levelsGCST904697121.18e-07
12264Physical activity (Total log acceleration 6pm-8pm)GCST900614181.15e-07
12265A4GALT levelsGCST904274571.15e-07
12266Positional arithmetic | Fluid intelligence / reasoningUKBB000006541.09e-07
12267Enthesopathy (PheCode 726.1)GCST904762391.08e-07
12268SNAP23/TXLNA ratioGCST903158571.07e-07
12269LGALS4/PCDH17 ratioGCST903153151.00e-07
12270Physical activityGCST900933249.94e-08
12271Influenza and pneumoniaFING000006799.65e-08
12272Total Dihexosylceramide levelsGCST900251939.14e-08
12273PBXIP1 levelsGCST904701647.72e-08
12274Fracture of lumbar spine and pelvisFING000005567.60e-08
12275DTX3 levelsGCST904690487.38e-08
12276TGFBR2/TNFRSF1A ratioGCST903159185.91e-08
12277IPCEF1/SPARC ratioGCST903151865.54e-08
12278Left-hemisphere limbic network to amygdala white-matter structural connectivityGCST903027415.47e-08
12279Other eye problems | EyesightUKBB000006104.42e-08
12280ADH4/KRT18 ratioGCST903131924.20e-08
12281LACRT levelsGCST904697254.13e-08
12282COL6A3/SPON2 ratioGCST903141793.87e-08
12283Coffee consumption (cups per day)GCST901329843.45e-08
12284ADAMTS8/FAP ratioGCST903131723.21e-08
12285F-dairy liking (derived food-liking factor)GCST900947513.21e-08
12286Biological Father: High blood pressureGCST904752432.91e-08
12287Intrinsic epigenetic age accelerationGCST900142902.87e-08
12288PDGFA/SCARF1 ratioGCST903156171.95e-08
12289CD160/CXCL16 ratioGCST903137281.93e-08
12290F2R/SERPINE1 ratioGCST903147351.78e-08
12291CD244/FCRL6 ratioGCST903137651.45e-08
12292Hypercalcemia (PheCode 275.6)GCST904757481.38e-08
12293RPN1 levelsGCST902409641.29e-08
12294IDP dMRI TBSS ISOVF Posterior corona radiata RGCST900045039.08e-09
12295VEGFB levelsGCST904710358.86e-09
12296SSC4D/TNFSF10 ratioGCST903158878.09e-09
12297Mineral and other dietary supplements - Calcium | MedicationUKBB000004717.45e-09
12298ICAM3/LY9 ratioGCST903151216.33e-09
12299GNS levelsGCST900884606.09e-09
12300ALCAM/ENPP2 ratioGCST903132364.80e-09
12301DSG3/NECTIN4 ratioGCST903145604.43e-09
12302GZMA/TNFRSF4 ratioGCST903150132.91e-09
12303Bacterial pneumoniaeFING000001392.66e-09
12304CD69/PLXNA4 ratioGCST903138802.33e-09
12305NPDC1/TAFA5 ratioGCST903155501.10e-09
12306BSG/LY9 ratioGCST903135346.85e-10
12307PDGFA/USP8 ratioGCST903156215.96e-10
12308IL10 levelsGCST904695465.90e-10
12309DKK1/PPCDC ratioGCST903144774.21e-10
12310Tyrosine levelsGCST905001562.68e-10
12311Lager likingGCST900947892.43e-10
12312CIAPIN1/VEGFC ratioGCST903140718.55e-11
12313HBEGF levelsGCST900120677.50e-12